We’re pleased to have been appointed by Florida-based biotech innovator Dyadic Applied BioSolutions to expand the company’s commercial presence in Japan and South Korea – two of Asia’s most advanced and fast-growing biopharmaceutical markets.
Dyadic develops precision-engineered, animal-free proteins and enzymes used across the life sciences, food and nutrition sectors and for industrial applications.
Building on its existing relationships with vaccine and biologics manufacturers in Asia, Dyadic is looking to introduce two high-value products with significant potential in Japan and South Korea. They are DNase 1 (RNase free), an enzyme used in biologics and mRNA manufacturing; and Human Transferrin, a recombinant version of transferrin widely used in research and cell culture media for biopharmaceutical production.
Our Tokyo and Seoul-based teams will lead targeted business development campaigns to identify, prioritise and engage partners, distributors and contract development and manufacturing organisations (CDMOs) for Dyadic. Their activities will establish direct supply relationships and platform licensing opportunities for the new products across the two markets.
Dyadic’s focus on Japan and South Korea aligns with strong regional trends. Both are investing heavily in biologics and cell and gene therapy (CGT) infrastructure, with a growing emphasis on the use of animal origin-free components for manufacturing consistency and regulatory compliance. South Korea’s rapidly expanding CDMO sector and Japan’s focus on innovation and quality present particularly attractive opportunities for Dyadic’s recombinant protein 
portfolio.
Joe Hazelton, President and Chief Operating Officer at Dyadic, said: “We see meaningful opportunities for our recombinant proteins in Japan and Korea as both countries continue to advance their biologics and CGT manufacturing capabilities.
“Intralink’s deep market knowledge and relationships will help accelerate our regional engagement and commercial progress.”
To discuss the prospects for your biotech business in Asia, please contact Corey Monteith at corey.monteith@intralinkgroup.com
